A new method for early prostate cancer treatment has been found recently. It has a number of positive features such as lower number of possible side-effects than existing therapies.
A study based on the sample of 41 male patients with prostate cancer diagnosis was published in the journal Lancet Oncology, argued that ultrasound treatment could reduce the risks, connected with common prostate cancer treatment, impotence, for instance.
Scientists suggest that these findings, if proved by further research may make a difference for the future of the prostate cancer treatment.
The Medical Research Council (MRC) funded the project. MRC officials said the results were fairly promising. There is about 37,000 men in the United Kingdom are diagnosed with prostate cancer each year.
The Prostate cancer kills 10,000 men per year, but some part of the cases show that there is a possible for men not treat prostate cancer.
The conventional treatment of the prostate cancer includes surgery or radiotherapy. The fact is that these methods are posing a significant threat to the overall health conditions because it can damage the tissues and may cause urinary incontinence and sexual dysfunction.
University College Hospital specialists from London have made first steps towards implementing of the new high-intensity ultrasound the focused on the cancer tumours. This was a "proof of concept" study involving 41 patients.
They used a probe, placed close to the prostate, which emits sound waves that heat the targeted cells to 80C, while causing minimal damage to surrounding nerves and muscles.
Hashim Ahmed, a urological surgeon at the trust who led the study, says the results, 12 months after treatment, are very encouraging.
"We've shown in this study that focal therapy - by targeting the individual areas of cancer - can avoid the collateral damage. We've shown that nine in 10 men had no impotence and none of the men in the study had incontinence of urine".
Mr Ahmed says the early evidence on cancer control is also very good. But he says this needs to be evaluated in much larger studies.
"This could offer a transformation of the way we treat prostate cancer. It could offer a cost-effective treatment for the NHS, and offer men with early prostate cancer an opportunity to treat their disease, but with very few side-effects".
A patient on the trial, 72-year-old Robert Page, from Croydon, says his treatment, two years ago, was a great success. "The outcome was very good," he said.
"I was very pleased with the treatment and very happy with the lack of side-effects, particularly when I contrast that with what might have been the case if I'd had one of the other, alternative, treatments".
The study was funded by the Medical Research Council, the Pelican Cancer Foundation and St Peter's Trust. Professor Gillies McKenna, director of the Gray Institute for Radiation Oncology and Biology, a joint collaboration between the MRC and Cancer Research UK, welcomed the findings.
"If these promising results can be confirmed in a randomised controlled trial, focal therapy could soon become a reasonable treatment choice for prostate cancer alongside other proven effective therapies".
The chief executive of the Prostate Cancer Charity, Owen Sharp, also emphasised the importance of further research. "We welcome the development of any prostate-cancer treatment which limits the possibility of damaging side-effects, such as incontinence and impotence. These early results certainly indicate that focal HIFU has the potential to achieve this in the future".
"However, we need to remember that this treatment was given to fewer than 50 men, without follow-up over a sustained period of time. We look forward to the results of further trials, which we hope will provide a clearer idea of whether this treatment can control cancer in the long term whilst ridding men of the fear that treating their cancer might mean losing their quality of life".
|Weekly consumption of oily fish rich in ... The essential omega-3 fatty acid abundant in oily fish ...|